Skip to content

LLLT for BCRL: a Randomized, Placebo-controlled Study

Large-area Low-level Laser Therapy for Breast Cancer-related Lymphedema: a Randomized, Placebo-controlled Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05725265
Enrollment
54
Registered
2023-02-13
Start date
2023-10-24
Completion date
2025-10-31
Last updated
2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Lymphedema

Keywords

Breast Cancer Lymphedema, Lymphedema, Breast cancer, Low level laser therapy

Brief summary

This study is conducted to compare between efficacy of large and small area of low-level laser therapy (LLLT) in treatment of post mastectomy lymphedema. The change of severity of BCRL will be measured by the difference of circumference and skin thickness, detected by ultrasound. The influence on clinical symptoms, such as pain, shoulder mobility and hand function, are also investigated in the study.

Detailed description

Breast cancer-related lymphedema (BCRL) is common complication after cancer treatment. The incidence of BCRL around is 16.6% (95% CI 13·6-20·2) after the diagnosis and higher among the group receiving the sentinel biopsy or axillary lymph dissection. The lymphedema arises from the accumulation of protein-rich lymph fluid in the interstitial spaces then results in chronic inflammation with symptoms of fibrosis, pain, limited range of motion or paresthesia. The BRCL is chronic and progressive condition, and the severity also changes over time. The definition and cut points of BCRL using inter-limb volume or arm circumference varied across the studies by different measure method. Currently, the International Society of Lymphology suggests calculating arm volume from circumferences through the truncated cone formula to qualify the severity. On the other hand, previous research found the skin and subcutis were thickened in the ipsilateral arm of patients with BCRL. Thus, the measurement of skin thickness using ultrasound may also practical to detect the progression of lymphedema. Except for physical change of upper limb, the symptoms of BCRL are also concerned. One of the most common morbidity is pain, mostly presenting 1 month after surgery (56.6%). Furthermore, BCRL might decrease shoulder range of motion. Previous study demonstrated that shoulder mobility was usually restricted at 1 month postoperatively and abduction and forward flexion were limited at first. Thus, functional disability may occurred and life of quality may be influenced. To evaluate the ability to perform functional activities, the Disability of Arm, Shoulder, and Hand Questionnaire (DASH) is an useful tool to assess the patients with BCRL. Currently, although complete decongestive therapy (CDT) has been the standard therapy, there is still various type of noninvasive treatment on BCRL, for example, low-level laser therapy (LLLT). Low-level laser therapy (LLLT), also named photobiomodulation therapy (PBMT), is a conservative therapy through utilizing wave lengths of red or near infrared light between 650 and 1000 nm to stimulate wound healing and reduce inflammation, edema, and pain. Moreover, the Food and Drug Administration (FDA) approved the use of the LLLT for treatment of postmastectomy lymphedema in November 2006. Previous studies have demonstrated the effect of LLLT on BCRL with comparison to physical therapy or placebo. However, there is still limited data about the LLLT with different light area on improvement of severity and symptoms of BCRL. Therefore, this study is conducted to compare between efficacy of large and small area of low-level laser therapy (LLLT) in treatment of post mastectomy lymphedema.

Interventions

DEVICELarge-area low-level laser therapy(Venusure)

The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions

DEVICEConventional low-level laser therapy

The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female subjects, 20 years age or older, suffered from unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection) * Stage I or II unilateral secondary upper extremity lymphedema(as defined by the International Society of Lymphology) * Girth≥ 2 cm circumferential difference compared with the uninvolved upper extremity at any 4 cm segment * Able to commit to a long-term follow-up schedule

Exclusion criteria

* Metastatic cancer(stage IV) * Pregnancy * Presence of other extremity lymphedema (primary or secondary) * History of deep vein thrombosis * Pacemaker * Artificial joints, implant or tattoo(area≥4 cm2) at the involved upper extremity * Previous treatment with low-level laser therapy (within 3 months) * Body mass index (BMI) \> 35 (morbid obesity) * High bleeding tendency(hemophilia) * Receiving long-term steroid treatment (oral or systemic)

Design outcomes

Primary

MeasureTime frameDescription
Circumference discrepancy of bilateral upper armDay 30 (change of circumference discrepancy of bilateral upper limbs, comparing with the data in baseline) of each sectionRecord the circumference of arm and forearm of involved and uninvolved upper extremity at 4 cm segment from cubital fossa and calculate the circumference discrepancy.

Secondary

MeasureTime frameDescription
visual analogue scale (VAS)Day 30, Day 60, Day 120 (comparing with the data in baseline) of each sectionRecord visual analogue scale (VAS) to rate the severity of pain. The total score ranges from 0 to 10. Higher score indicates greater pain intensity.
Range of motion of involved shoulderDay 30, Day 60, Day 120 (comparing with the data in baseline) of each sectioninvolved upper extremity.
Skin thicknessDay 30, Day 60, Day 120 (comparing with the data in baseline) of each sectionUse ultrasound to measure the skin thickness of arm and forearm of involved upper extremity.
QuickDASHDay 30, Day 60, Day 120 (comparing with the data in baseline) of each sectionQuickDASH(Quick Disabilities of Arm, Shoulder & Hand) is a questionnaire for patients presenting with self-reported disabilities of the arm, shoulder and hand. The QuickDASH contains 11-items; the score of each item ranges from 1 to 5 and total score ranges from 0 to 100. Higher score indicates greater level of disability and severity.

Countries

Taiwan

Contacts

Primary ContactYing-Chun Chen, MD
yasandy2000@gmail.com23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026